Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Complex President Moksha Fitzgibbons explains how the brand is blending media, AI, e-commerce, sports & live experiences to build a new kind of culture business
Amazon’s Daniel Rausch, VP of Alexa and Echo, on Alexa’s AI evolution, the future of voice commerce and why your next shopping assistant could be Alexa.
PlantSwitch CEO Dillon Baxter reveals how agricultural byproducts like rice hulls and wheat straw could help replace plastics with plant-based alternatives.
Nugget ice is booming across America. Middleby CEO Tim FitzGerald explains the craze, restaurant demand and why the trend could become a major growth engine.
Wearable robotics are moving beyond sci-fi. Dephy CEO Luke Mooney explains how its smart ankle exoskeleton is changing mobility, recovery and everyday movement.
